Psychotropic Drugs
13
4
4
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
15%
2 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (13)
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Association Between Intake of Psychotropic Medications and Risk of Falls in Older Adults
Decreasing Harms and Improving Child Health
National Pregnancy Registry for Psychiatric Medications
Drugs Experience for Adolescents With Anorexia
SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®
ORiginal meThodology for Assessing the Impact of the Coronavirus Health Crisis on Psychotropic Drug Use
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
Relative Bioavailability of LY03010 Compared to Listed Drug
Remimazolam Improves the Safety in Elderly Patients Undergoing Gastrointestinal Endoscopy
Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs
Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)